Shattuck Labs, Inc. (STTK) – What Are Researchers Saying About This Stock?

Shares of Shattuck Labs, Inc. (NASDAQ:STTK) have been given an average recommendation of “Buy” by the thirteen brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, nine have issued a buy recommendation and three have given a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $13.70.

STTK has been the subject of a number of recent research reports. Raymond James Financial assumed coverage on shares of Shattuck Labs in a research note on Monday, August 24th. They set a “strong-buy” rating and a $18.00 price objective for the company. JPMorgan Chase & Co. initiated coverage on Shattuck Labs in a report on Friday, July 24th. They issued an “overweight” rating and a $10.00 price target for the company. Needham & Company LLC upped their price objective on Shattuck Labs from $17.00 to $19.00 and gave the company a “buy” rating in a research report on Friday, October 2nd. UBS Group initiated coverage on Shattuck Labs in a research note on Sunday, October 11th. They set a “buy” rating and a $17.00 price objective on the stock. Finally, Leerink Partners began coverage on Shattuck Labs in a research note on Monday, July 20th. They set an “outperform” rating and a $16.00 price objective on the stock.

Institutional Investors Weigh In On Shattuck Labs

Hedge funds have recently modified their holdings of the company. BlackRock Inc. purchased a new stake in shares of Shattuck Labs in the second quarter valued at $27,315,000. Frazier Life Sciences Management L.P. acquired a new stake in Shattuck Labs in the 2nd quarter valued at $26,025,000. Pinnacle Associates Ltd. grew its stake in shares of Shattuck Labs by 12.2% in the third quarter. Pinnacle Associates Ltd. now owns 2,099,779 shares of the company’s stock valued at $14,320,000 after buying an additional 228,337 shares in the last quarter. Wellington Management Group LLP purchased a new stake in shares of Shattuck Labs during the second quarter valued at approximately $12,269,000. Finally, Renaissance Technologies LLC increased its stake in Shattuck Labs by 77.4% during the 1st quarter. Renaissance Technologies LLC now owns 604,500 shares of the company’s stock worth $3,887,000 after buying an additional 263,800 shares during the period. 58.74% of the stock is owned by institutional investors and hedge funds.

Shattuck Labs Stock Up 0.9%

Shares of Shattuck Labs stock opened at $5.54 on Tuesday. Shattuck Labs has a 52-week low of $1.72 and a 52-week high of $8.33. The company’s 50-day simple moving average is $6.42 and its 200-day simple moving average is $5.99. The firm has a market cap of $555.99 million, a price-to-earnings ratio of -10.86 and a beta of 1.09.

Shattuck Labs (NASDAQ:STTK) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.12) EPS for the quarter, meeting analysts’ consensus estimates of ($0.12). Equities research analysts anticipate that Shattuck Labs will post -0.45 EPS for the current year.

Shattuck Labs Company Profile

Shattuck Labs, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The company’s research is based on its Agonist Redirected Checkpoint (ARC) platform, which is designed to combine immune-cell activation with checkpoint inhibition in a single therapeutic molecule.

Shattuck’s pipeline has included bifunctional fusion proteins such as SL-172154, an investigational therapy designed to engage CD40 ligand and block PD-L1, and SL-173154, which is designed to target CD27 ligand and PD-L1.